

**RECEIVED**  
**CENTRAL FAX CENTER**

**FEB 06 2006**

---

**FACSIMILE MESSAGE - PLEASE DELIVER PROMPTLY**

---

February 6, 2006

TO: Examiner Maryam Monshipouri  
Group 1653  
571-272-0932

FROM Justin D. Karjala  
Celera Genomics Corp.  
(240) 453-3812

FAX NO: (571) 273-8300

# OF PAGES (incl. cover): 6

---

Re: U.S. Serial No. 10/663,794, filed September 17, 2003  
Entitled "ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID  
MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES  
THEREOF"  
Atty. Docket No.: CL001164CIP-DIVII

A Preliminary Amendment (Restriction Election) in the above-identified application follows. No fee is due for this submission.

---

*The information contained within this facsimile message is intended only for the personal and confidential use of the designated recipient named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and return the original message to us by mail.*

**RECEIVED**  
**CENTRAL FAX CENTER**

FEB 06 2006

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Ming-Hui WEI et al.

Serial No.: 10/663,794

Filed: September 17, 2003

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

Art Unit: 1653

Examiner: M. Monshipouri

Atty. Docket: CL001164CIP-DIVII

**PRELIMINARY AMENDMENT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

*By Facsimile*

Sir:

This is in response to an Office Action mailed on January 4, 2006 from Examiner Monshipouri in which a restriction requirement was issued for the above-referenced application.

Applicants hereby elect claim group II (claims 3 and 12, directed to antibodies and methods of detecting polypeptides using antibodies, etc.) for examination and have canceled claims corresponding to the non-elected groups I and III-VIII.

Please amend the application as follows: